MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer | Zendy

Cheng Pang | Zendy; Ming Liu | Zendy; Weiwei Fang | Zendy; Jun Guo | Zendy; Zhipeng Zhang | Zendy; Pengjie Wu | Zendy; Yaoguang Zhang | Zendy; Jianye Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer

Author(s) -

Cheng Pang,

Ming Liu,

Weiwei Fang,

Jun Guo,

Zhipeng Zhang,

Pengjie Wu,

Yaoguang Zhang,

Jianye Wang

Publication year - 2016

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000447819

Subject(s) - prostate cancer , medicine , pathological , biomarker , hyperplasia , microrna , receiver operating characteristic , carcinogenesis , peripheral blood , oncology , cancer , prostate , area under the curve , pathology , gastroenterology , biology , gene , biochemistry

Emerging evidence suggested that microRNAs (miRNAs) play a causal role in cancer tumorigenesis. Aberrant expression of miRNA (miR)-139-5p has been observed in various types of cancers. The present study evaluated the relationship between miR-139-5p expression levels and prostate cancer (PCa), to assess the feasibility of using peripheral blood miR-139-5p as a potential non-invasive biomarker for PCa.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research